Shares of Sarepta Therapeutics (SRPT) have soared 43% year to date, significantly outperforming the industry’s 6.9% decline. The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. SRPT’s shares are trading above the 50 and 200-day moving averages.SRPT Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThe surge in the stock price can be attributed to the encouraging sales performance of Duchenne muscular dystrophy (D ...

Shares of Sarepta Therapeutics (SRPT) rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals .ARWR Deal Expands Sarepta’s PipelinePer the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical development. These programs are being developed against a broad range of genetic diseases in ...

Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $185.45 indicates a potential upside of 42.1%.The mean estimate comprises 20 short-term price targets with a standard deviation of $31.14. While the lowest estimate of $80 indicates a 38.7% decline from the ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Financial Data and Key Metrics Changes - Total net product revenue for Q3 2024 was approximately $430 million, representing a 39% increase compared to the same quarter last year [8] - Net product revenue from ELEVIDYS was $181 million, a significant increase from $69 million in Q3 2023 [52] - Non-GAAP net income for Q3 2024 was $67 million or $0.62 per diluted share, compared to $31.5 million or $0.31 per diluted share in Q3 2023 [54] Business Line Data and Key Metrics Changes - PMO sales, including EXONDYS 51, VYONDYS 53, and AMONDYS 45, achieved approximately $249 million in Q3 2024, with a 4% growth compared to Q3 2023 [10][24] - EXONDYS 51 led the PMO franchise with $140.7 million in net product revenue, while VYONDYS 53 and AMONDYS 45 generated $32.2 million and $75.9 million, respectively [25] Market Data and Key Metrics Changes - The company reported strong patient demand from both ambulant and non-ambulant populations, with a three to five-month conversion timeline for patient access [18] - The company has approximately 75 sites for dosing, with the majority actively treating patients [99] Company Strategy and Development Direction - The company has rationalized and prioritized its R&D pipeline, discontinuing the SRP-5051 program while advancing other programs for limb-girdle muscular dystrophy [12][43] - The company aims for a BLA filing in 2025 for SRP-9003 and is progressing with trials for SRP-9004 and SRP-9005 [14][39][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting Q4 expectations and reiterated long-term guidance of $3 billion in revenue for 2025, with a peak year sales projection of $5 billion or more [63] - The management highlighted the importance of payer interactions and the quality of discussions with both Medicaid and commercial payers [80] Other Important Information - The company reported approximately $1.4 billion in cash, cash equivalents, investments, and long-term restricted cash as of September 30, 2024 [59] - The company expects to be sustainably profitable from both GAAP and non-GAAP perspectives and anticipates turning cash flow positive early in 2025 [60][91] Q&A Session Summary Question: Clarification on Q4 guidance - Management confirmed that they are comfortable with the guidance provided for Q4, expecting 100% upside based on Q3 performance [63] Question: Details on PPMO discontinuation - The decision to discontinue the PPMO program was based on safety concerns, including hypomagnesemia, and the evolving landscape for Duchenne treatments [68][70] Question: Progress on ELEVIDYS launch - Management noted that they have treated a significant number of patients and are optimistic about Q4 sales exceeding guidance [75] Question: Medicaid coverage policies - Approximately 50% of patients with Duchenne muscular dystrophy are on Medicaid, and discussions with payers have been productive [80] Question: Site capacity and dosing - Management indicated that about 75 sites are available for dosing, with the majority actively treating patients [99] Question: Lifecycle management of PMOs - Management clarified that they are not moving away from exon-skipping therapies and remain committed to enhancing their PMO offerings [102][106]

Sarepta Therapeutics (SRPT) reported $467.17 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 40.8%. EPS of $0.62 for the same period compares to -$0.46 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $399.88 million, representing a surprise of +16.83%. The company delivered an EPS surprise of +513.33%, with the consensus EPS estimate being -$0.15.While investors closely watch year-over-year changes in headline numbers -- revenue ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other ...

These two could become direct competitors relatively soon. Wave Life Sciences (WVE 6.39%) and Sarepta Therapeutics (SRPT 0.15%) are both riskier than the typical biotech, even when considering their stage of maturity. But with more uncertainty often comes more upside for risk-tolerant investors, and both companies are without a doubt on the very forefront of medicine, pushing the envelope beyond what was previously possible. Still, there's a clear winner here from an investment perspective, so let's analyze ...

I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...

Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. Investing in biotech companies, especially relatively small ones, can be a double-edged sword. Their shares often soar on strong clinical trial or regulatory news, but they can lose much of their value overnight if a study's results don't go their way. That makes many biotech stocks somewhat risky investments, but some could deliver excellent results for those who can stomach the risk. Two biotech co ...